This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Diabetes technology company Dexcom began sales of its ...

(Reuters) -Dexcom said on Monday its over-the-counter continuous glucose monitor, Stelo, is now available for use in the United States at a price of up to $99. Stelo was cleared by the U.S. health ...

It’s here: Dexcom is kicking off the international rollout of the newest generation of its real-time continuous glucose monitor, the G7, to help adults and children with diabetes digitally track their ...

Stifel resumed coverage with a Buy rating, highlighting the potential of DexCom’s 15-day sensor and growing market share in the Type 2 diabetes segment. TD Cowen also reiterated a Buy rating and a ...

To follow up on what it’s described as its “best year ever,” Dexcom has accelerated the development of the newest version of its mainstay continuous glucose monitor in 2021—and delivered new clinical ...

DexCom, Inc. (NASDAQ:DXCM) is one of the 10 best healthcare equipment stocks to buy according to hedge funds. On February 13, William Plovanic from Canaccord Genuity reduced the price target on DexCom ...

In other recent news, DexCom has been the focus of various analyst reports and market reactions regarding its G7 continuous glucose monitoring device. UBS maintained its Buy rating for DexCom, setting ...